ETFs Lineage Cell Therapeutics, Inc.

LCTX

US53566P1093

Biotechnology & Medical Research

Market Closed - NYSE 01:00:00 14/11/2026 +04			5-day change	1st Jan Change
0.9146 ^USD	-7.64%		-10.33%	-45.23%

11-13	Lineage Cell Therapeutics, Inc., Q3 2026 Earnings Call, Nov 12, 2026
11-13	Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI

ETFs positioned on Lineage Cell Therapeutics, Inc.

Name	YTD change	Weight	AuM
ISHARES BIOTECHNOLOGY ETF - USD	+25.91%	0.04%	9,953 M€
VANGUARD EXTENDED MARKET ETF - USD	+9.97%	0%	32,130 M€
STATE STREET SPDR RUSSELL 2000 U.S. SMALL CAP UCITS ETF - USD	+14.17%	0%	5,739 M€
LEUTHOLD CORE ETF - USD	+4.65%	0%	68 M€
VANGUARD MORNINGSTAR TOTAL STOCK MARKET ETF - USD	+10.69%	0%	692,025 M€
VANGUARD MORNINGSTAR U.S. TOTAL MARKET INDEX ETF - CAD	+14.99%	0%	14,144 M€
VANGUARD GROWTH ETF PORTFOLIO - CAD	+10.74%	0%	7,793 M€
UPAR ULTRA RISK PARITY ETF - USD	-4.53%	0%	59 M€
VANGUARD ALL-EQUITY ETF PORTFOLIO - CAD	+15.34%	0%	12,086 M€
ELM MARKET NAVIGATOR ETF - USD	+6.50%	0%	594 M€
VANGUARD CONSERVATIVE ETF PORTFOLIO - CAD	+3.66%	0%	688 M€
VANGUARD BALANCED ETF PORTFOLIO - CAD	+8.06%	0%	4,204 M€
DEFINED DURATION 20 ETF - USD	+10.89%	0%	19 M€
RPAR RISK PARITY ETF - USD	-2.02%	0%	580 M€
CAMBRIA TAX AWARE ETF - USD	+7.55%	0%	26 M€
VANGUARD CONSERVATIVE INCOME ETF PORTFOLIO - CAD	+0.22%	0%	184 M€
VANGUARD RETIREMENT INCOME ETF PORTFOLIO - CAD	+1.08%	0%	267 M€
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD	+3.68%	0%	37 M€
ISHARES LIFEPATH TARGET DATE 2030 ETF - USD	+5.19%	0%	80 M€
CLEARSHARES OCIO ETF - DISTRIBUTING - USD	+5.42%	0%	176 M€
AB US EQUITY ETF - USD	+8.37%	0%	727 M€
ALPHA ARCHITECT US EQUITY 2 ETF - USD	+8.89%	0%	513 M€
CAMBRIA US EW ETF - USD	+10.57%	0%	194 M€
DEFINED DURATION 5 ETF - USD	+0.07%	0%	18 M€
CAMBRIA GLOBAL EW ETF - USD	+8.47%	0%	146 M€
CAMBRIA ENDOWMENT STYLE ETF - USD	+10.15%	0%	156 M€
WARREN STREET GLOBAL EQUITY ETF - USD	+11.87%	-.--%	62 M€

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and associated development and manufacturing capabilities. AlloSCOPE platform, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or substantially identical to cells found naturally in the human body. The Company's pipeline includes OpRegen, HUNT1, OPC1, ReSonance, COR1, ILT1, PNC1, and RND1. OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD), HUNT1, a pluripotent stem cell derived, neural cell therapy in Phase 1b/2a development for the treatment of Huntingtonâ€™s Disease.

Employees

Sector

Biotechnology & Medical Research

More about the company